KR102854980B1 - 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주 - Google Patents

약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주

Info

Publication number
KR102854980B1
KR102854980B1 KR1020187019759A KR20187019759A KR102854980B1 KR 102854980 B1 KR102854980 B1 KR 102854980B1 KR 1020187019759 A KR1020187019759 A KR 1020187019759A KR 20187019759 A KR20187019759 A KR 20187019759A KR 102854980 B1 KR102854980 B1 KR 102854980B1
Authority
KR
South Korea
Prior art keywords
respiratory syncytial
syncytial virus
rsv
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187019759A
Other languages
English (en)
Korean (ko)
Other versions
KR20180085803A (ko
Inventor
피터 엘. 콜린스
우르술라 제이. 부흐홀츠
신디 루온고
Original Assignee
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 filed Critical 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Priority to KR1020257029082A priority Critical patent/KR20250134719A/ko
Publication of KR20180085803A publication Critical patent/KR20180085803A/ko
Application granted granted Critical
Publication of KR102854980B1 publication Critical patent/KR102854980B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187019759A 2015-12-11 2016-12-12 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주 Active KR102854980B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257029082A KR20250134719A (ko) 2015-12-11 2016-12-12 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562266199P 2015-12-11 2015-12-11
US62/266,199 2015-12-11
PCT/US2016/066146 WO2017100759A1 (en) 2015-12-11 2016-12-12 Recombinant respiratory syncytial virus strains with mutations in the m2-2 orf providing a range of attenuation phenotypes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257029082A Division KR20250134719A (ko) 2015-12-11 2016-12-12 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주

Publications (2)

Publication Number Publication Date
KR20180085803A KR20180085803A (ko) 2018-07-27
KR102854980B1 true KR102854980B1 (ko) 2025-09-03

Family

ID=57714677

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187019759A Active KR102854980B1 (ko) 2015-12-11 2016-12-12 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주
KR1020257029082A Pending KR20250134719A (ko) 2015-12-11 2016-12-12 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257029082A Pending KR20250134719A (ko) 2015-12-11 2016-12-12 약독화 표현형의 범위를 제공하는 m2-2 orf 변이를 가지는 재조합 호흡기 세포융합 바이러스 균주

Country Status (9)

Country Link
US (2) US10655109B2 (enExample)
EP (1) EP3386539A1 (enExample)
JP (2) JP7079197B2 (enExample)
KR (2) KR102854980B1 (enExample)
CN (1) CN109310752B (enExample)
AR (1) AR106956A1 (enExample)
AU (1) AU2016366771B2 (enExample)
CA (1) CA3007408A1 (enExample)
WO (1) WO2017100759A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630173A1 (en) * 2017-05-29 2020-04-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
US20230279362A1 (en) * 2020-06-05 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Live attenuated respiratory syncytial virus
AU2024380679A1 (en) 2023-11-17 2026-07-02 Sanofi Vaccines US Inc. Trehalose vaccine formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US20040005542A1 (en) * 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
WO2002044334A2 (en) * 2000-11-28 2002-06-06 Aviron, Inc. Recombinant rsv virus expression systems and vaccines
DE10118446A1 (de) * 2001-04-12 2002-10-17 Thomas Hartung Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen
PL3511015T3 (pl) 2012-04-13 2021-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetycznie stabilna żywa atenuowana szczepionka przeciw syncytialnemu wirusowi oddechowemu i jej wytwarzanie
WO2015041924A2 (en) * 2013-09-18 2015-03-26 Medimmune, Llc Recombinant respiratory syncytial virus (rsv) and caccines
US10947512B2 (en) 2015-08-14 2021-03-16 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered NS1 protein function and related materials and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF VIROLOGY, 1997, pp. 8973-8982.*
SCIENCE TRANSLATIONAL MEDICINE, 2015.11.04., vol. 7, no. 312, pp. 1-9.*

Also Published As

Publication number Publication date
RU2018125246A3 (enExample) 2020-05-25
CN109310752B (zh) 2022-12-16
BR112018011674A2 (pt) 2018-12-04
US20190040365A1 (en) 2019-02-07
US11332721B2 (en) 2022-05-17
AR106956A1 (es) 2018-03-07
JP2018536428A (ja) 2018-12-13
JP7079197B2 (ja) 2022-06-01
US20200283740A1 (en) 2020-09-10
CN109310752A (zh) 2019-02-05
JP7357709B2 (ja) 2023-10-06
RU2018125246A (ru) 2020-01-15
KR20180085803A (ko) 2018-07-27
KR20250134719A (ko) 2025-09-11
CA3007408A1 (en) 2017-06-15
WO2017100759A1 (en) 2017-06-15
AU2016366771B2 (en) 2022-04-07
EP3386539A1 (en) 2018-10-17
AU2016366771A1 (en) 2018-07-12
JP2022088376A (ja) 2022-06-14
US10655109B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
AU2020203460B2 (en) Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
AU2021218112B2 (en) Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
KR102567994B1 (ko) 재조합 rsv 생백신주 및 이의 제조 방법
KR20110063863A (ko) 생 약독화 호흡기 세포융합 바이러스
CN113322264A (zh) 具有沉默突变的重组rsv、其相关疫苗和方法
JP7357709B2 (ja) さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株
KR20210005090A (ko) 키메라 벡터
US11918638B2 (en) Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
KR20230021115A (ko) 생 약독화된 호흡기 세포융합 바이러스 (live attenuated respiratory syncytial virus)
KR20230038205A (ko) 키메라 rsv 및 코로나바이러스 단백질, 면역원성 조성물, 및 사용 방법
RU2773746C2 (ru) Рекомбинантные штаммы респираторно-синцитиального вируса с мутациями в м2-2 orf, обеспечивающими диапазон аттенуирующих фенотипов
BR112018011674B1 (pt) Vírus sincicial respitatório (rsv) recombinante, seu método de produção, seus usos, bem como molécula de polinucleotídeo isolada, vetor e composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)